<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Non-falciparum malaria: Plasmodium knowlesi
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Non-falciparum malaria: Plasmodium knowlesi
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Non-falciparum malaria: Plasmodium knowlesi
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nicholas M Anstey, MBBS, FRACP, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bridget Emily Barber, MBBS, MPH, FRACP, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy William, MBBS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Johanna Daily, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 26, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1863622304">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Plasmodium knowlesi
         </em>
         is a simian malaria parasite; the natural hosts are macaques [
         <a href="#rid1">
          1
         </a>
         ]. Human cases of knowlesi malaria have been reported throughout Southeast Asia; the greatest number of cases have been reported from Malaysia, particularly the eastern Malaysian states of Sabah and Sarawak [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Human
         <em>
          P. knowlesi
         </em>
         infection is generally acquired in forest or forest-fringe areas; those at risk include farmers, plantation workers, and individuals undertaking other activities in forested areas [
         <a href="#rid3">
          3
         </a>
         ]. Clinical disease occurs more commonly in adults than in children [
         <a href="#rid3">
          3-7
         </a>
         ]; the risk of severe disease increases with age [
         <a href="#rid6">
          6,8
         </a>
         ].
        </p>
        <p>
         Issues related to non-falciparum malaria due to
         <em>
          P. knowlesi
         </em>
         are reviewed here [
         <a href="#rid9">
          9,10
         </a>
         ]. Issues related to non-falciparum malaria due to
         <em>
          Plasmodium vivax, Plasmodium ovale,
         </em>
         and
         <em>
          Plasmodium malariae
         </em>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">
          "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H463928145">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3451033369">
         <span class="h2">
          Geographic distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first case of naturally acquired human infection with
         <em>
          P. knowlesi
         </em>
         was reported in 1965 in a United States national working in Malaysia [
         <a href="#rid11">
          11
         </a>
         ]. Subsequently, a large focus of naturally acquired
         <em>
          P. knowlesi
         </em>
         infections in humans in the eastern Malaysian state of Sarawak was described in 2004 [
         <a href="#rid12">
          12
         </a>
         ]. Following this report,
         <em>
          P. knowlesi
         </em>
         was found to be widely distributed throughout Sarawak and the other eastern Malaysian state of Sabah as well as in Peninsular Malaysia [
         <a href="#rid13">
          13
         </a>
         ]. The infections occurred in patients who had been diagnosed by microscopy as infected with
         <em>
          P. malariae
         </em>
         , which is morphologically similar. A map of the predicted risk of
         <em>
          P. knowlesi
         </em>
         infection throughout Southeast Asia is provided in the figure  (
         <a class="graphic graphic_figure graphicRef115652" href="/z/d/graphic/115652.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The geographic distribution of
         <em>
          P. knowlesi
         </em>
         reflects that of the simian hosts, the long-tailed macaque (
         <em>
          Macaca fascicularis
         </em>
         ) and pig-tailed macaque (
         <em>
          Macaca nemestrina
         </em>
         ), and the mosquito vector (
         <em>
          Anopheles leucosphyrus
         </em>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. These macaque species have a geographic distribution that extends from India, Bhutan, and Bangladesh eastwards through to the Philippines and southwards to Indonesia. The
         <em>
          An. leucosphyrus
         </em>
         group mosquitoes have a similar distribution across this region.
        </p>
        <p>
         Human cases of
         <em>
          P. knowlesi
         </em>
         have been reported throughout this region, including in Myanmar, Thailand, Cambodia, southern China, Vietnam, Laos, Philippines, Singapore, Malaysia, Brunei, the Andaman Islands in India, and Kalimantan and Sumatra, Indonesia [
         <a href="#rid15">
          15-20
         </a>
         ]. An increasing number of cases have also been reported in travelers returning from these regions [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         The greatest number of cases have been reported in the eastern Malaysian state of Sabah [
         <a href="#rid23">
          23
         </a>
         ]. In this state,
         <em>
          P. knowlesi
         </em>
         has become the predominant cause of human malaria; cases of
         <em>
          P. falciparum
         </em>
         and
         <em>
          P. vivax
         </em>
         have fallen substantially [
         <a href="#rid4">
          4,5,7,24
         </a>
         ]. In 2017, there were 2030 cases of
         <em>
          P. knowlesi
         </em>
         reported in Sabah accounting for 98 percent of reported cases [
         <a href="#rid7">
          7
         </a>
         ], with over 4000 cases of knowlesi malaria reported nationally [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3881578288">
         <span class="h2">
          Transmission and risk factors for infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Humans are incidentally infected with
         <em>
          P. knowlesi
         </em>
         when bitten by a mosquito vector that has fed from a macaque reservoir host. Human-mosquito-human transmission has been demonstrated in a laboratory setting but has not yet been proven to occur in the natural environment [
         <a href="#rid26">
          26
         </a>
         ]. Human cases of
         <em>
          P. knowlesi
         </em>
         have been reported to occur in clusters, with individuals of all ages affected; therefore, while transmission is predominantly zoonotic, it appears possible that human-mosquito-human transmission may occur (at least to some degree) in endemic areas [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Risk factors for acquiring
         <em>
          P. knowlesi
         </em>
         malaria include [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≥15 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Work involving farming, plantations, or clearing vegetation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleeping outside
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proximity to monkeys in the preceding four weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of open eaves or gaps in walls
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of long grass around dwelling
        </p>
        <p>
        </p>
        <p>
         Protective factors against
         <em>
          P. knowlesi
         </em>
         malaria in one study included glucose-6-phosphate dehydrogenase (G6PD) deficiency, residual insecticide spraying of household walls, and presence of sparse forest or rice paddies around the house; use of bed nets was not protective [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Most clinical cases of
         <em>
          P. knowlesi
         </em>
         infection occur in adults [
         <a href="#rid6">
          6,24,28,29
         </a>
         ]; children &lt;15 years accounted for only 6 percent of all
         <em>
          P. knowlesi
         </em>
         cases in Sabah, Malaysia, between 2015 and 2017 [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Travelers from nonendemic countries have acquired
         <em>
          P. knowlesi
         </em>
         infection in Malaysia, Thailand, Indonesia, and the Philippines [
         <a href="#rid21">
          21,22
         </a>
         ]. The majority of these cases have occurred in men who have spent time in forested regions. (See
         <a class="medical medical_review" href="/z/d/html/3886.html" rel="external">
          "Approach to illness associated with travel to Southeast Asia"
         </a>
         .)
        </p>
        <p>
         Transfusion-transmitted
         <em>
          P. knowlesi
         </em>
         malaria has been reported in Malaysia [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2574693641">
         <span class="h2">
          Life cycle
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anopheline mosquitoes become infected with
         <em>
          P. knowlesi
         </em>
         parasites after ingesting sexual-stage parasites from infected macaque monkeys. The life cycle of
         <em>
          P. knowlesi
         </em>
         infection in humans begins when a female anopheline mosquito injects saliva containing sporozoites during a human blood meal  (
         <a class="graphic graphic_figure graphicRef115650" href="/z/d/graphic/115650.html" rel="external">
          figure 2
         </a>
         ). The sporozoites travel through the host's bloodstream to the liver, where they invade hepatocytes, undergo asexual replication, and develop into schizonts. Hepatic schizonts rupture and release thousands of daughter merozoites into the bloodstream, causing fever and an inflammatory response.
         <em>
          P. knowlesi
         </em>
         does not form latent hypnozoite stages.
        </p>
        <p>
         Merozoites then invade erythrocytes where they develop into young ring parasites and then trophozoites, which undergo further asexual multiplication to form schizonts, containing numerous merozoites. The infected erythrocyte then ruptures, releasing merozoites, which reinvade uninfected erythrocytes, completing the first erythrocytic replication cycle. Within the erythrocyte, some of the merozoites develop into male and female gametocytes. In nonhuman primates (naturally) and human primates (at least experimentally) these gametocytes are taken up by a female mosquito and undergo sexual replication within the midgut of the mosquito to complete the life cycle.
        </p>
        <p>
         The erythrocytic phase of the
         <em>
          P. knowlesi
         </em>
         life cycle lasts 24 hours, which is the shortest duration of any human malaria species. Therefore, patients with
         <em>
          P. knowlesi
         </em>
         experience daily fever spikes, and high parasitemia may develop rapidly.
        </p>
        <p class="headingAnchor" id="H1765424253">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrum of clinical disease due to
         <em>
          P. knowlesi
         </em>
         infection ranges from asymptomatic infection to severe disease. Most patients have uncomplicated disease; severe disease occurs in 6 to 9 percent of symptomatic adults but has not been observed in children [
         <a href="#rid6">
          6,28,29
         </a>
         ]. Fatal infection can occur, particularly in the setting of delayed treatment [
         <a href="#rid13">
          13,24,29,31-33
         </a>
         ].
        </p>
        <p>
         The incubation period of
         <em>
          P. knowlesi
         </em>
         infection is usually 8 to 12 days (range of 3 to 27 days) [
         <a href="#rid34">
          34-36
         </a>
         ]. Parasites normally appear in the blood several days after the initial temperature rise. In a study of experimental mosquito infection, pre-patent periods (time to detectable parasitemia) of 9 to 12 days were reported [
         <a href="#rid26">
          26
         </a>
         ]. In hospital-based studies, the average duration of fever prior to presentation is five days [
         <a href="#rid6">
          6,29,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2082101697">
         <span class="h2">
          Nonpregnant adults
         </span>
        </p>
        <p class="headingAnchor" id="H3155318781">
         <span class="h3">
          Uncomplicated infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For purposes of clinical management, uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria is defined as clinical illness with parasitemia &lt;15,000/uL and no features of severe malaria. (See
         <a class="local">
          'Severe infection'
         </a>
         below.)
        </p>
        <p>
         Clinical manifestations of
         <em>
          P. knowlesi
         </em>
         infection in adults include fever (100 percent), chills, headache (89 to 92 percent), myalgia (62 percent), nausea (56 percent), abdominal pain (23 to 51 percent), vomiting (24 to 32 percent), diarrhea (8 percent), and cough (35 to 52 percent) [
         <a href="#rid6">
          6,29,37,38
         </a>
         ]. Physical findings include fever, tachycardia, and tachypnea. Splenomegaly and hepatomegaly are present in 6 to 33 percent and 24 to 40 percent of patients, respectively [
         <a href="#rid6">
          6,29,37
         </a>
         ].
        </p>
        <p>
         Neurologic manifestations are rare in
         <em>
          P. knowlesi
         </em>
         infection. In the three prospective case series including 674 adults with
         <em>
          P. knowlesi
         </em>
         infection (including 56 with severe disease), none had unarousable coma or seizures [
         <a href="#rid6">
          6,29,37,38
         </a>
         ]. Case reports of coma or focal neurologic signs have been described [
         <a href="#rid24">
          24,29
         </a>
         ]; however, absence of neuroimaging, lumbar puncture, and other diagnostic workup precluded exclusion of alternative diagnoses.
        </p>
        <p>
         Retinopathy has been described in association with
         <em>
          P. knowlesi
         </em>
         infection. In one series including 44 patients with
         <em>
          P. knowlesi
         </em>
         infection, retinal hemorrhages were observed in 18 percent of cases and were associated with thrombocytopenia [
         <a href="#rid39">
          39
         </a>
         ]. However, the characteristic retinal whitening seen in severe falciparum malaria has not been observed in knowlesi malaria.
        </p>
        <p class="headingAnchor" id="H2178070831">
         <span class="h3">
          Severe infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Criteria for severe
         <em>
          P. knowlesi
         </em>
         infection are summarized in the table  (
         <a class="graphic graphic_table graphicRef115654" href="/z/d/graphic/115654.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10,37,40,41
         </a>
         ].
         <em>
          P. knowlesi
         </em>
         parasitemia &gt;15,000/microL is a strong independent risk factor for severe malaria [
         <a href="#rid6">
          6
         </a>
         ]. In a prospective study including more than 400 patients in Malaysia with
         <em>
          P. knowlesi
         </em>
         infection, parasitemia &gt;15,000/microL was the best predictor of disease severity (odds ratio 16; negative predictive value 98 percent) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         In the setting of parasitemia &gt;100,000/microL, the risk of severe disease is increased 28-fold [
         <a href="#rid37">
          37
         </a>
         ]. The likelihood of hyperparasitemia correlates with age, with age ≥45 years being the best predictor of hyperparasitemia [
         <a href="#rid6">
          6
         </a>
         ]. Older adults have higher parasitemias and thus are at greater risk of severe disease [
         <a href="#rid8">
          8,37
         </a>
         ].
        </p>
        <p>
         Clinical manifestations of severe disease include jaundice, acute kidney injury, respiratory distress, and shock [
         <a href="#rid15">
          15
         </a>
         ]. Severe acute kidney injury (creatinine &gt;3 mg/dL [265 micromol/L]) occurs in 30 to 94 percent of adults with severe disease [
         <a href="#rid6">
          6,29,31,37,42
         </a>
         ]. Blackwater fever with acute kidney injury has been described [
         <a href="#rid31">
          31,37,43
         </a>
         ]. Respiratory distress is associated with hyperparasitemia and occurs in 7 to 70 percent of patients with severe disease [
         <a href="#rid6">
          6,29,31,37,42
         </a>
         ]. Thrombocytopenia may rarely be associated with significant bleeding [
         <a href="#rid6">
          6,13,29,37,44,45
         </a>
         ]. Concurrent gram-negative bacteremia has been observed in severe
         <em>
          P. knowlesi
         </em>
         infection [
         <a href="#rid31">
          31,32
         </a>
         ]. Rarely, spontaneous splenic rupture can occur, presenting with fever and an acute abdomen [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         The case-fatality rate of
         <em>
          P. knowlesi
         </em>
         malaria in the era of
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         treatment is approximately 0.2 to 0.4 percent [
         <a href="#rid6">
          6,7,24,33
         </a>
         ]. Earlier diagnosis and early use of artesunate therapy is associated with lower case-fatality rates [
         <a href="#rid24">
          24,33
         </a>
         ]. Death due to
         <em>
          P. knowlesi
         </em>
         infection occurs most commonly in older adults [
         <a href="#rid13">
          13,24,29,31,32
         </a>
         ], and age ≥45 years and female sex have been reported as independent risk factors for death. Patients who are pregnant or have underlying cardiovascular disease and diabetes may also be at increased risk. Thrombocytopenia, acute kidney injury, and hyponatremia have been observed in all reported fatal cases, with the majority also having abdominal pain and metabolic acidosis [
         <a href="#rid13">
          13,24,32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3511702746">
         <span class="h3">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory investigations include hematologic studies and assessment of renal function, liver function, and acid-base status.
        </p>
        <p>
         Anemia (hemoglobin &lt;10 g/dL) occurs in 5 to 28 percent of cases [
         <a href="#rid29">
          29,37
         </a>
         ]. Severe anemia (&lt;7 g/dL) has been reported in 1.5 to 1.7 percent of cases overall and in 5 to 29 percent of those with severe malaria [
         <a href="#rid6">
          6,29,37
         </a>
         ].
        </p>
        <p>
         Thrombocytopenia (platelet count &lt;150 x 10
         <sup>
          3
         </sup>
         /microL) occurs routinely in
         <em>
          P. knowlesi
         </em>
         malaria. In three large series including 674 adults hospitalized with knowlesi malaria, thrombocytopenia occurred in 94 percent of cases [
         <a href="#rid6">
          6,29,37
         </a>
         ]; platelet count &lt;50 x 10
         <sup>
          3
         </sup>
         /microL occurred in 29 to 60 percent of cases [
         <a href="#rid29">
          29,37
         </a>
         ]. Platelet counts generally recover quickly, and bleeding occurs in only 4 to 5 percent of those with severe malaria [
         <a href="#rid29">
          29,37
         </a>
         ]. Hematemesis, however, has been observed in patients with severe disease [
         <a href="#rid13">
          13,37,44,47
         </a>
         ]. Absence of thrombocytopenia has been observed in some asplenic patients, suggesting a role of the spleen in platelet destruction or clearance [
         <a href="#rid30">
          30,37,43,47
         </a>
         ].
        </p>
        <p>
         White blood cell counts are usually normal; neutrophilia has been observed in severe disease [
         <a href="#rid6">
          6,8,37
         </a>
         ].
        </p>
        <p>
         Coagulation studies may be abnormal. In one series of patients requiring tertiary hospital admission, including 22 patients with severe disease, significant elevations of the prothrombin and partial thromboplastin times were observed in 32 percent of cases, although none had clinically important bleeding [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Acute kidney injury is common, occurring in 19 percent of cases [
         <a href="#rid6">
          6
         </a>
         ]. Severe acute kidney injury (creatinine &gt;3 mg/dL [265 micromol/L]) occurs in 36 to 54 percent of patients with severe malaria [
         <a href="#rid6">
          6,31,37
         </a>
         ]. Metabolic acidosis occurs in 11 to 32 percent of cases requiring tertiary hospitalization [
         <a href="#rid31">
          31,37
         </a>
         ].
        </p>
        <p>
         Mild elevations of liver transaminases are common [
         <a href="#rid6">
          6,29,37
         </a>
         ]. In two series, hyperbilirubinemia (&gt;2.46 mg/dL [&gt;42 micromol/L]) was observed in 3 percent of hospital presentations and in 53 percent of patients with severe infection [
         <a href="#rid29">
          29,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2936852948">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. knowlesi
         </em>
         malaria in children is relatively uncommon [
         <a href="#rid6">
          6,24,28,29
         </a>
         ]. In one study including 3262 cases in Sabah, Malaysia, between 2015 and 2017, 6 percent occurred in children [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Children typically present with fever [
         <a href="#rid6">
          6,48
         </a>
         ]. Clinical manifestations are similar to those in adults, including rigors (66 percent), headache (77 percent), abdominal pain (43 percent), cough (34 percent), vomiting (32 percent), arthralgia (27 percent), and myalgia (25 percent) [
         <a href="#rid6">
          6
         </a>
         ]. Thrombocytopenia and mild to moderate anemia are common [
         <a href="#rid6">
          6,48
         </a>
         ]. In one series including 31 children, hemoglobin ≤7 g/dL was observed 7 percent of cases [
         <a href="#rid6">
          6
         </a>
         ]. Parasitemia is usually low [
         <a href="#rid6">
          6,15,37
         </a>
         ].
        </p>
        <p>
         Severe disease has not been observed in children, and no coma or pediatric deaths have been reported [
         <a href="#rid6">
          6,7,24,33,48,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2234807279">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. knowlesi
         </em>
         infection during pregnancy appears to be relatively uncommon [
         <a href="#rid31">
          31,33,50
         </a>
         ]. Adverse maternal and infant outcomes have been described, including maternal death, severe maternal malaria, fetal loss, and low birth weight.
        </p>
        <p class="headingAnchor" id="H2673827734">
         <span class="h2">
          Asymptomatic infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic infection has been observed in endemic areas among adults and children [
         <a href="#rid17">
          17,18,51,52
         </a>
         ]. The proportion of asymptomatic individuals in northeastern Sabah, Malaysia, has been estimated to be 7 percent [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1623954686">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. knowlesi
         </em>
         malaria should be suspected in the setting of febrile illness after exposure to regions where
         <em>
          P. knowlesi
         </em>
         malaria is endemic  (
         <a class="graphic graphic_figure graphicRef115652" href="/z/d/graphic/115652.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The approach to diagnosis of
         <em>
          P. knowlesi
         </em>
         malaria consists of microscopy to guide immediate clinical management, followed by confirmatory testing with polymerase chase reaction (PCR) in a reference laboratory if feasible. PCR is the gold standard diagnostic tool with excellent sensitivity and specificity [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         Microscopy is a sensitive tool for the diagnosis of malaria and may be used to detect all species; it allows determination of parasitemia and the life cycle stages present  (
         <a class="graphic graphic_table graphicRef53291" href="/z/d/graphic/53291.html" rel="external">
          table 2
         </a>
         ). However, microscopy cannot be reliably used for distinguishing
         <em>
          P. knowlesi
         </em>
         from other species  (
         <a class="graphic graphic_figure graphicRef80296" href="/z/d/graphic/80296.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid4">
          4,32,55,56
         </a>
         ]. The blood stages of
         <em>
          P. knowlesi
         </em>
         resemble
         <em>
          P. malariae
         </em>
         and the ring stages resemble
         <em>
          P. falciparum
         </em>
         .
        </p>
        <p>
         Because
         <em>
          P. knowlesi
         </em>
         may be indistinguishable from
         <em>
          P. malariae
         </em>
         on microscopy, patients with exposure to regions where
         <em>
          P. knowlesi
         </em>
         malaria is endemic and microscopy findings resembling
         <em>
          P. malariae
         </em>
         should be treated for
         <em>
          P. knowlesi
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">
          "Laboratory tools for diagnosis of malaria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">
          "Non-falciparum malaria: P. vivax, P. ovale, and P. malariae", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         The limit of detection of microscopy is about 20 parasites/microL in expert hands. Available data suggest it would be unlikely for a patient to present with acute illness and parasitemia below the limit of detection of microscopy. Competent microscopy requires ongoing training and evaluation and proper supplies and equipment.
        </p>
        <p>
         Rapid diagnostic tests (RDTs) are useful for excluding
         <em>
          P. falciparum
         </em>
         infection but have poor sensitivity for detection of
         <em>
          P. knowlesi
         </em>
         infection, particularly at the low parasite densities commonly causing clinical disease [
         <a href="#rid57">
          57-59
         </a>
         ]. Available RDTs are unable to distinguish
         <em>
          P. knowlesi
         </em>
         from other non-falciparum species [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3592481452">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of malaria is outlined separately. (See
         <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">
          "Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1359240066">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, all adults with known or suspected
         <em>
          P. knowlesi
         </em>
         infection should be admitted to hospital for management, because of the significant risk of severe disease at relatively low parasitemia and the risk of developing complications after commencement of treatment [
         <a href="#rid29">
          29,37
         </a>
         ]. We are in agreement with Malaysian Ministry of Health Guidelines which require hospital admission for all adults, particularly those &gt;40 years of age [
         <a href="#rid8">
          8,37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2427527948">
         <span class="h2">
          Antimalarial selection
         </span>
        </p>
        <p class="headingAnchor" id="H1133672839">
         <span class="h3">
          Adults
         </span>
        </p>
        <p class="headingAnchor" id="H4094566455">
         <span class="h4">
          Uncomplicated infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For clinical purposes, uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria is defined as clinical illness with parasitemia &lt;15,000 parasites/microL and no features of severe malaria  (
         <a class="graphic graphic_table graphicRef115654" href="/z/d/graphic/115654.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The preferred therapy for treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         infection consists of an oral artemisinin combination therapy (ACT) regimen [
         <a href="#rid9">
          9,10,60
         </a>
         ]. Patients unable to tolerate oral intake should be treated with parenteral therapy as described below. (See
         <a class="local">
          'Severe infection'
         </a>
         below.)
        </p>
        <p>
         ACTs are superior to
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         for treatment of drug-resistant
         <em>
          P. falciparum
         </em>
         and
         <em>
          P. vivax
         </em>
         malaria found in coendemic regions [
         <a href="#rid61">
          61,62
         </a>
         ]. Given that, in
         <em>
          P. knowlesi
         </em>
         –endemic areas,
         <em>
          P. falciparum
         </em>
         and
         <em>
          P. vivax
         </em>
         are commonly misdiagnosed as
         <em>
          P. knowlesi
         </em>
         , use of chloroquine for the treatment of microscopy-diagnosed "
         <em>
          P. knowlesi
         </em>
         " malaria may result in inadvertent administration of chloroquine for misdiagnosed
         <em>
          P. falciparum
         </em>
         or
         <em>
          P. vivax
         </em>
         infection [
         <a href="#rid17">
          17,18,56
         </a>
         ]. ACTs for treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria are summarized in the table  (
         <a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">
          Artemether-lumefantrine
         </a>
         is the preferred ACT for treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria, given its excellent efficacy, tolerability, and wide availability [
         <a href="#rid31">
          31,37
         </a>
         ]. In a randomized trial including 123 patients with uncomplicated
         <em>
          P. knowlesi
         </em>
         infection treated with artemether-lumefantrine or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         , those treated with artemether-lumefantrine had faster parasite clearance (18 versus 24 hours; p = 0.02) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other ACTs used successfully for treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria include artesunate-mefloquine and dihydroartemisinin-piperaquine. In a randomized trial including 252 patients with uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria treated with artesunate-mefloquine or
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         , those treated with artesunate-mefloquine had faster parasite clearance (18 versus 24 hours), faster fever clearance (11 versus 14 hours), and lower risk of anemia within 28 days (71 versus 83 percent) [
         <a href="#rid28">
          28
         </a>
         ]. Successful use of dihydroartemisinin-piperaquine has been described [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Alternative drugs for treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria include
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         [
         <a href="#rid28">
          28,40,61
         </a>
         ] and
         <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">
          atovaquone-proguanil
         </a>
         [
         <a href="#rid22">
          22,66-69
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          Chloroquine
         </a>
         is efficacious for treatment of
         <em>
          P. knowlesi
         </em>
         infection but has been associated with slower parasite clearance times and a higher frequency of anemia than ACTs [
         <a href="#rid12">
          12,28,40,63
         </a>
         ]. Adult dosing of chloroquine consists of a total dose of 25 mg base/kg administered as 10 mg base/kg orally on day 1, followed by 10 mg base/kg orally on day 2, and 5 mg base/kg on day 3. Minor side effects of chloroquine (including bitter taste, gastrointestinal disturbances, dizziness, blurred vision, and headache) may be alleviated by taking the drug with food. (See
         <a class="medical medical_review" href="/z/d/html/468.html" rel="external">
          "Antimalarial drugs: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         , the hydroxyl analogue of
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         , has similar properties and activity to chloroquine and in vitro has similar efficacy against chloroquine-sensitive
         <em>
          P. falciparum
         </em>
         [
         <a href="#rid70">
          70
         </a>
         ]. It is likely to be effective; its use for the treatment of
         <em>
          P. knowlesi
         </em>
         malaria has not been described.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">
          Atovaquone-proguanil
         </a>
         has been used for the treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria in returned travelers, with rapid recovery reported in all cases [
         <a href="#rid66">
          66-69
         </a>
         ]. Adult dosing of atovaquone-proguanil consists of four adult tabs (250 mg
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         /100 mg proguanil) orally once daily for three days.
        </p>
        <p>
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         has been used successfully to treat uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria; however, we do not recommend its use (with
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ) as first-line treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria, given significantly slower parasite clearance times than with ACT [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Successful treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria with
         <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">
          mefloquine
         </a>
         has been described [
         <a href="#rid71">
          71,72
         </a>
         ]. However, treatment failures have been reported in rhesus macaques [
         <a href="#rid73">
          73,74
         </a>
         ]. We are in agreement with the World Health Organization, which favors use of mefloquine as an artemisinin partner drug and discourages mefloquine monotherapy [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         No molecular evidence of drug resistance in
         <em>
          P. knowlesi
         </em>
         has been identified to date [
         <a href="#rid16">
          16,75-77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H889853449">
         <span class="h4">
          Severe infection
         </span>
        </p>
        <p class="headingAnchor" id="H1117334877">
         <span class="h5">
          Antimalarial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial management of patients with features of severe
         <em>
          P. knowlesi
         </em>
         malaria  (
         <a class="graphic graphic_table graphicRef115654" href="/z/d/graphic/115654.html" rel="external">
          table 1
         </a>
         ) or with parasitemia &gt;15,000 parasites/microL consists of parenteral therapy [
         <a href="#rid21">
          21,41
         </a>
         ]. Parenteral therapy is also warranted for patients unable to tolerate oral intake. (See
         <a class="local">
          'Severe infection'
         </a>
         above.)
        </p>
        <p>
         Treatment of severe malaria (caused by any species) consists of parenteral
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study at a tertiary hospital in Malaysia including 16 patients with severe
         <em>
          P. knowlesi
         </em>
         malaria treated with intravenous
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         (before intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         was available), 31 percent of patients died [
         <a href="#rid31">
          31
         </a>
         ]. In a subsequent prospective study at the same hospital including 38 patients with severe
         <em>
          P. knowlesi
         </em>
         malaria treated with intravenous artesunate, all patients survived [
         <a href="#rid37">
          37
         </a>
         ]. Following statewide implementation of intravenous artesunate in Malaysia, the case-fatality rate due to
         <em>
          P. knowlesi
         </em>
         malaria between 2010 and 2014 fell from 9.2 to 1.6/1000 case notifications [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         for treatment of severe
         <em>
          P. knowlesi
         </em>
         malaria is also supported by randomized trials among adults and children in Southeast Asia [
         <a href="#rid78">
          78
         </a>
         ] and African children [
         <a href="#rid79">
          79
         </a>
         ] demonstrating reduced mortality with intravenous artesunate compared with intravenous
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         for the treatment of severe
         <em>
          P. falciparum
         </em>
         malaria.
        </p>
        <p>
        </p>
        <p>
         The optimal approach for treatment of patients with parasitemia &gt;15,000 parasites/microL in the absence of other evidence of severe disease is uncertain. For such patients, we favor at least one dose of intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         , given the increased risk of severe malaria associated with moderately high parasite counts.
        </p>
        <p>
         For patients meeting criteria for severe disease, intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         should be administered for a minimum of three doses; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef79194" href="/z/d/graphic/79194.html" rel="external">
          table 4
         </a>
         ). Intravenous therapy should be followed by a three-day course of oral ACT once oral intake is tolerated. (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria"
         </a>
         .)
        </p>
        <p>
         If intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         is not available, intravenous
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         is an acceptable alternative therapy; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef79194" href="/z/d/graphic/79194.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria"
         </a>
         .)
        </p>
        <p>
         Patients treated with parenteral therapy because of inability to tolerate oral intake (in the absence of other criteria for severe malaria) may be switched from intravenous therapy to a three-day course of oral ACT regimen as soon as oral intake is tolerated.
        </p>
        <p class="headingAnchor" id="H3331312955">
         <span class="h5">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe
         <em>
          P. knowlesi
         </em>
         malaria may be associated with multiorgan failure requiring intensive supportive care, including inotropic and ventilatory support [
         <a href="#rid31">
          31
         </a>
         ] and hemodialysis for acute kidney injury [
         <a href="#rid31">
          31,37
         </a>
         ].
        </p>
        <p>
         Intravenous fluids should be administered conservatively [
         <a href="#rid80">
          80
         </a>
         ]. There have been no clinical trials to guide intravenous fluid management in
         <em>
          P. knowlesi
         </em>
         malaria; our approach is extrapolated from studies of severe
         <em>
          P. falciparum
         </em>
         malaria in which liberal administration of intravenous fluids has been shown to be deleterious [
         <a href="#rid80">
          80,81
         </a>
         ] and conservative fluid regimens have been shown to be safe [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         For patients with severe knowlesi malaria, we include adjunctive treatment with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         (500 to 1000 mg every 6 hours for 72 hours). This approach is supported by a randomized trial including more than 390 patients with severe knowlesi malaria; improved renal function was observed among those with hemolysis and acute kidney injury who received regularly dosed acetaminophen (creatinine fell by 31 versus 20 percent) [
         <a href="#rid83">
          83
         </a>
         ], as also shown previously in severe falciparum malaria [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Empiric broad-spectrum intravenous antibiotics are commonly administered in severe
         <em>
          P. knowlesi
         </em>
         malaria until blood cultures are negative [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Platelet counts generally recover rapidly after commencement of antimalarial treatment [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3071226439">
         <span class="h3">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to selection of antimalarial therapy for children with uncomplicated
         <em>
          P. knowlesi
         </em>
         infection is the same as for adults. (See
         <a class="local">
          'Uncomplicated infection'
         </a>
         above.)
        </p>
        <p>
         Dosing of oral ACT regimens is summarized in the table  (
         <a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">
          table 3
         </a>
         ). Pediatric dosing of
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         consists of 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours (total dose 25 mg base/kg; maximum total dose 1500 mg base [=2500 mg salt]). Pediatric dosing of
         <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">
          atovaquone
         </a>
         is weight-based (5 to 8 kg: 2 pediatric tabs orally once daily for three days; 9 to 10 kg: 3 pediatric tabs orally once daily for three days; 11 to 20 kg: 1 adult tab orally once daily for three days; 21 to 30 kg: 2 adult tabs orally once daily for three days; 31 to 40 kg: 3 adult tabs orally once daily for three days).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          Hydroxychloroquine
         </a>
         has similar properties and activity to
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         and in vitro has similar efficacy against chloroquine-sensitive
         <em>
          P. falciparum
         </em>
         [
         <a href="#rid70">
          70
         </a>
         ]. It is likely to be effective; its use for the treatment of
         <em>
          P. knowlesi
         </em>
         malaria has not been described.
        </p>
        <p>
         Oral
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         has been used successfully to treat uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria in children [
         <a href="#rid48">
          48
         </a>
         ]; however, we do not recommend its use as first-line treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria, given significantly slower parasite clearance times than with ACT [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Use of intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         is warranted for children who do not tolerate oral intake [
         <a href="#rid37">
          37,78,79
         </a>
         ]. As soon as oral intake is tolerated, treatment may be switched from intravenous therapy to a three-day course of oral ACT regimen.
        </p>
        <p>
         Severe disease due to
         <em>
          P. knowlesi
         </em>
         infection in children has not been described; therefore, there is no experience regarding use of intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         for this indication. However, children with severe malaria from any species warrant treatment with intravenous artesunate; further principles for management of severe malaria in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1354308628">
         <span class="h3">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of pregnant women with uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria in the second or third trimester consists of an oral ACT regimen;
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         is an acceptable alternative [
         <a href="#rid10">
          10
         </a>
         ]. Treatment of pregnant women with uncomplicated
         <em>
          P. knowlesi
         </em>
         malaria in the first trimester consists of chloroquine. Drug dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef107719" href="/z/d/graphic/107719.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         Pregnant women with severe malaria (due to any species) should be treated with intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         , regardless of trimester [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
         If there is any doubt as to the species diagnosis, treatment for
         <em>
          P. falciparum
         </em>
         infection should be administered [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">
          "Malaria in pregnancy: Prevention and treatment", section on 'Uncomplicated P. falciparum malaria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2556115300">
         <span class="h2">
          Follow-up monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood smears should be repeated daily until parasitemia has cleared. Parasite clearance is usually rapid; median parasite clearance times for knowlesi malaria of 18 hours for
         <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">
          artemether-lumefantrine
         </a>
         and 24 hours for
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         have been described [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         In patients with prior splenectomy, parasite clearance can be prolonged despite clinical improvement [
         <a href="#rid37">
          37
         </a>
         ]. This is due to delayed removal of dead circulating parasites, rather than treatment failure.
        </p>
        <p>
         Antimalarial drug resistance has not been reported in zoonotic malaria. For patients with recurrent parasitemia due to reinfection, a repeat course of antimalarial therapy should be administered [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         For patients with severe malaria, careful monitoring including complete blood count, renal and liver function, venous blood gases, and oxygenation saturation should be monitored until end organ dysfunction resolves.
        </p>
        <p>
         Delayed hemolytic anemia after
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         therapy of falciparum malaria has been described; it is not known whether this occurs after treatment of knowlesi malaria. For this reason, patients treated with intravenous artesunate should be monitored with repeat hemoglobin testing at 7, 14, and 30 days after treatment [
         <a href="#rid10">
          10,85,86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2633272727">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113035.html" rel="external">
          "Society guideline links: Malaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1556270334">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Plasmodium knowlesi
         </em>
         is a simian malaria parasite; the natural hosts are macaques. Human cases of knowlesi malaria have been reported throughout Southeast Asia  (
         <a class="graphic graphic_figure graphicRef115652" href="/z/d/graphic/115652.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Humans are incidentally infected with
         <em>
          P. knowlesi
         </em>
         when bitten by a mosquito vector that has fed from a macaque reservoir host  (
         <a class="graphic graphic_figure graphicRef115650" href="/z/d/graphic/115650.html" rel="external">
          figure 2
         </a>
         ). Human
         <em>
          P. knowlesi
         </em>
         infection is generally acquired in forest or forest-fringe areas; those at risk include farmers, plantation workers, and individuals undertaking other activities in forested areas. Most cases of
         <em>
          P. knowlesi
         </em>
         infection occur in adults. (See
         <a class="local">
          'Transmission and risk factors for infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The spectrum of clinical disease due to
         <em>
          P. knowlesi
         </em>
         infection ranges from asymptomatic infection to severe disease. The incubation period of
         <em>
          P. knowlesi
         </em>
         infection is usually 8 to 12 days. Clinical manifestations of
         <em>
          P. knowlesi
         </em>
         infection include fever, chills, headache, myalgia, nausea, abdominal pain, vomiting, diarrhea, and cough. Physical findings include fever, tachycardia, and tachypnea; splenomegaly and hepatomegaly are observed in some cases. Most patients have uncomplicated disease, defined as clinical illness with parasitemia &lt;15,000/uL and no features of severe malaria. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="local">
          'Uncomplicated infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe disease occurs in a minority of adults but has not been observed in children. Clinical manifestations of severe disease include jaundice, acute kidney injury, respiratory distress, and shock. Criteria for severe
         <em>
          P. knowlesi
         </em>
         infection are summarized in the table  (
         <a class="graphic graphic_table graphicRef115654" href="/z/d/graphic/115654.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          P. knowlesi
         </em>
         malaria should be suspected in the setting of febrile illness after exposure to regions where
         <em>
          P. knowlesi
         </em>
         malaria is endemic. The approach to diagnosis consists of microscopy (to guide immediate clinical management), followed by confirmatory testing with polymerase chase reaction in a reference laboratory (if feasible). Microscopy cannot be reliably used for distinguishing
         <em>
          P. knowlesi
         </em>
         from other species  (
         <a class="graphic graphic_figure graphicRef80296" href="/z/d/graphic/80296.html" rel="external">
          figure 3
         </a>
         ). Therefore, patients with relevant epidemiologic exposure and microscopy findings resembling
         <em>
          P. malariae
         </em>
         should be treated for
         <em>
          P. knowlesi
         </em>
         infection. Rapid diagnostic tests are useful for excluding
         <em>
          P. falciparum
         </em>
         infection but have poor sensitivity for detection of
         <em>
          P. knowlesi
         </em>
         infection. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults with known or suspected
         <em>
          P. knowlesi
         </em>
         infection should be admitted to the hospital for management because of the significant risk of severe disease at relatively low parasitemia and the risk of developing complications after commencement of treatment. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of uncomplicated
         <em>
          P. knowlesi
         </em>
         infection, we suggest an oral artemisinin combination therapy (ACT) regimen (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ); regimens are summarized in the table  (
         <a class="graphic graphic_table graphicRef107830" href="/z/d/graphic/107830.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Uncomplicated infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial treatment of severe malaria consists of parenteral therapy. We suggest intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         (in areas where intravenous artesunate of reliable quality is readily available) rather than intravenous
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_4" rel="external">
          Grade 2A
         </a>
         ); dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef79194" href="/z/d/graphic/79194.html" rel="external">
          table 4
         </a>
         ). Intravenous therapy should be followed by a three-day course of an oral ACT regimen once oral intake is tolerated. (See
         <a class="local">
          'Severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of patients with parasitemia &gt;15,000 parasites/microL in the absence of other evidence for severe disease, we suggest at least one dose of intravenous
         <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">
          artesunate
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given the increased risk of severe malaria associated with moderately high parasite counts. (See
         <a class="local">
          'Severe infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          P. knowlesi
         </em>
         does not form hypnozoite liver stages; therefore, anti-relapse therapy is not required. (See
         <a class="local">
          'Life cycle'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Napier LE, Campbell HGM. Observations on a Plasmodium Infection Which Causes Hæmoglobinuria in Certain Species of Monkey. Ind Med Gaz 1932; 67:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shearer FM, Huang Z, Weiss DJ, et al. Estimating Geographical Variation in the Risk of Zoonotic Plasmodium knowlesi Infection in Countries Eliminating Malaria. PLoS Negl Trop Dis 2016; 10:e0004915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, Cox J, William T, et al. Individual-level factors associated with the risk of acquiring human Plasmodium knowlesi malaria in Malaysia: a case-control study. Lancet Planet Health 2017; 1:e97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           William T, Jelip J, Menon J, et al. Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malar J 2014; 13:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           William T, Rahman HA, Jelip J, et al. Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Negl Trop Dis 2013; 7:e2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, William T, Barber BE, et al. Age-Related Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of Severity. Clin Infect Dis 2018; 67:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper DJ, Rajahram GS, William T, et al. Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species. Clin Infect Dis 2020; 70:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, Grigg MJ, William T, et al. Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria. J Infect Dis 2017; 215:1908.
          </a>
         </li>
         <li class="breakAll">
          Ministry of Health Malaysia. Management Guidelines of Malaria in Malaysia Vector Borne Disease Sector, Disease Control Division, Ministry of Health, Malaysia 2014. http://www.moh.gov.my/english.php/pages/view/118 (Accessed on September 07, 2017).
         </li>
         <li class="breakAll">
          Guidelines for the Treatment of Malaria, World Health Organization, Geneva 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHIN W, CONTACOS PG, COATNEY GR, KIMBALL HR. A NATURALLY ACQUITED QUOTIDIAN-TYPE MALARIA IN MAN TRANSFERABLE TO MONKEYS. Science 1965; 149:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004; 363:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008; 46:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyes CL, Shearer FM, Huang Z, et al. Predicting the geographical distributions of the macaque hosts and mosquito vectors of Plasmodium knowlesi malaria in forested and non-forested areas. Parasit Vectors 2016; 9:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013; 26:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyagi RK, Das MK, Singh SS, Sharma YD. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. J Antimicrob Chemother 2013; 68:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lubis IND, Wijaya H, Lubis M, et al. Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. J Infect Dis 2017; 215:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herdiana H, Cotter C, Coutrier FN, et al. Malaria risk factor assessment using active and passive surveillance data from Aceh Besar, Indonesia, a low endemic, malaria elimination setting with Plasmodium knowlesi, Plasmodium vivax, and Plasmodium falciparum. Malar J 2016; 15:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwagami M, Nakatsu M, Khattignavong P, et al. First case of human infection with Plasmodium knowlesi in Laos. PLoS Negl Trop Dis 2018; 12:e0006244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh GJ, Ismail PK, Koh D. Occupationally Acquired Plasmodium knowlesi Malaria in Brunei Darussalam. Saf Health Work 2019; 10:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, Grigg MJ, William T, et al. The Treatment of Plasmodium knowlesi Malaria. Trends Parasitol 2017; 33:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Froeschl G, Nothdurft HD, von Sonnenburg F, et al. Retrospective clinical case series study in 2017 identifies Plasmodium knowlesi as most frequent Plasmodium species in returning travellers from Thailand to Germany. Euro Surveill 2018; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussin N, Lim YA, Goh PP, et al. Updates on malaria incidence and profile in Malaysia from 2013 to 2017. Malar J 2020; 19:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajahram GS, Barber BE, William T, et al. Falling Plasmodium knowlesi Malaria Death Rate among Adults despite Rising Incidence, Sabah, Malaysia, 2010-2014. Emerg Infect Dis 2016; 22:41.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization World Malaria Report 2018. https://www.who.int/tb/publications/global_report/en/ (Accessed on January 07, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chin W, Contacos PG, Collins WE, et al. Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey. Am J Trop Med Hyg 1968; 17:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, William T, Dhararaj P, et al. Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. Malar J 2012; 11:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, William T, Menon J, et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infect Dis 2016; 16:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009; 49:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bird EM, Parameswaran U, William T, et al. Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report. Malar J 2016; 15:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011; 17:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajahram GS, Barber BE, William T, et al. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J 2012; 11:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajahram GS, Cooper DJ, William T, et al. Deaths From Plasmodium knowlesi Malaria: Case Series and Systematic Review. Clin Infect Dis 2019; 69:1703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowles R, Das Gupta BM. A study of monkey-malaria and its experimental transmission to man. Ind Med Gaz 1932; 67:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rooyen CE, Pile GR. OBSERVATIONS ON INFECTION BY PLASMODIUM KNOWLESI (APE MALARIA) IN THE TREATMENT OF GENERAL PARALYSIS OF THE INSANE. Br Med J 1935; 2:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milam DF, Coggeshall LT. Duration of Plasmodium knowlesi infections in man. Am J Trop Med Hyg 1938; 18:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshvar C, William T, Davis TME. Clinical features and management of Plasmodium knowlesi infections in humans. Parasitology 2018; 145:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govindasamy G, Barber BE, Ghani SA, et al. Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria. J Infect Dis 2016; 213:1476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010; 9:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Severe malaria. Trop Med Int Health 2014; 19 Suppl 1:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willmann M, Ahmed A, Siner A, et al. Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study. Malar J 2012; 11:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, Grigg MJ, William T, et al. Intravascular haemolysis with haemoglobinuria in a splenectomized patient with severe Plasmodium knowlesi malaria. Malar J 2016; 15:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ninan T, Nalees K, Newin M, et al. Plasmodium knowlesi malaria infection in human. Brunei International Medical Journal 2012; 8:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CE, Adeeba K, Freigang G. Human Plasmodium knowlesi infections in Klang Valley, Peninsula Malaysia: a case series. Med J Malaysia 2010; 65:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CY, Pui WC, Kadir KA, Singh B. Spontaneous splenic rupture in Plasmodium knowlesi malaria. Malar J 2018; 17:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boo YL, Lim HT, Chin PW, et al. A case of severe Plasmodium knowlesi in a splenectomized patient. Parasitol Int 2016; 65:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, William T, Jikal M, et al. Plasmodium knowlesi malaria in children. Emerg Infect Dis 2011; 17:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas NM, Lampah DA, Kenangalem E, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med 2013; 10:e1001575; discussion e1001575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, Bird E, Wilkes CS, et al. Plasmodium knowlesi malaria during pregnancy. J Infect Dis 2015; 211:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchand RP, Culleton R, Maeno Y, et al. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among Humans and Anopheles dirus Mosquitoes, Southern Vietnam. Emerg Infect Dis 2011; 17:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornace KM, Nuin NA, Betson M, et al. Asymptomatic and Submicroscopic Carriage of Plasmodium knowlesi Malaria in Household and Community Members of Clinical Cases in Sabah, Malaysia. J Infect Dis 2016; 213:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imwong M, Tanomsing N, Pukrittayakamee S, et al. Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol 2009; 47:4173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, Lubis IN, Tetteh KKA, et al. Plasmodium knowlesi detection methods for human infections-Diagnosis and surveillance. Adv Parasitol 2021; 113:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malar J 2009; 8:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, William T, Grigg MJ, et al. Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013; 12:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barber BE, William T, Grigg MJ, et al. Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax. J Clin Microbiol 2013; 51:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, William T, Barber BE, et al. Combining parasite lactate dehydrogenase-based and histidine-rich protein 2-based rapid tests to improve specificity for diagnosis of malaria Due to Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia. J Clin Microbiol 2014; 52:2053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster D, Cox-Singh J, Mohamad DS, et al. Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malar J 2014; 13:60.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, William T, Menon J, et al. Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clin Infect Dis 2016; 62:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, William T, Barber BE, et al. Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. Clin Infect Dis 2018; 66:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setiadi W, Sudoyo H, Trimarsanto H, et al. A zoonotic human infection with simian malaria, Plasmodium knowlesi, in Central Kalimantan, Indonesia. Malar J 2016; 15:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herdiana H, Irnawati I, Coutrier FN, et al. Two clusters of Plasmodium knowlesi cases in a malaria elimination area, Sabang Municipality, Aceh, Indonesia. Malar J 2018; 17:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis 2010; 16:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrhardt J, Trein A, Kremsner P, Frank M. Plasmodium knowlesi and HIV co-infection in a German traveller to Thailand. Malar J 2013; 12:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoosen A, Shaw MT. Plasmodium knowlesi in a traveller returning to New Zealand. Travel Med Infect Dis 2011; 9:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackroth MS, Tappe D, Tannich E, et al. Rapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi. Open Forum Infect Dis 2016; 3:ofw039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warhurst DC, Steele JC, Adagu IS, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bronner U, Divis PC, Färnert A, Singh B. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malar J 2009; 8:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abanyie FA, McCracken C, Kirwan P, et al. Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children. Malar J 2013; 12:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripathi R, Awasthi A, Dutta GP. Mefloquine resistance reversal action of ketoconazole - a cytochrome P450 inhibitor, against mefloquine-resistant malaria. Parasitology 2005; 130:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh PP, Dutta GP. Antimalarial activity of mefloquine and chloroquine against blood induced Plasmodium knowlesi infection in rhesus monkeys. Indian J Med Res 1981; 73 Suppl:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigg MJ, Barber BE, Marfurt J, et al. Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS One 2016; 11:e0149519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assefa S, Lim C, Preston MD, et al. Population genomic structure and adaptation in the zoonotic malaria parasite Plasmodium knowlesi. Proc Natl Acad Sci U S A 2015; 112:13027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fatih FA, Staines HM, Siner A, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar J 2013; 12:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson J, Anstey NM, Bihari D, et al. The fluid management of adults with severe malaria. Crit Care 2014; 18:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson JP, Lam SW, Mohanty S, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on Acid-base status, renal function, and extravascular lung water. Crit Care Med 2013; 41:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aung NM, Kaung M, Kyi TT, et al. The Safety of a Conservative Fluid Replacement Strategy in Adults Hospitalised with Malaria. PLoS One 2015; 10:e0143062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper DJ, Grigg MJ, Plewes K, et al. The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in Plasmodium knowlesi Malaria (PACKNOW): A Randomized, Controlled Trial. Clin Infect Dis 2022; 75:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plewes K, Kingston HWF, Ghose A, et al. Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clin Infect Dis 2018; 67:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauréguiberry S, Ndour PA, Roussel C, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Junyent J, Ruiz-Panales P, Calvo-Cano A, et al. Delayed haemolysis after artesunate therapy in a cohort ofpatients with severe imported malaria due to Plasmodiumfalciparum. Enferm Infecc Microbiol Clin 2015.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 112633 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29011028" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Observations on a Plasmodium Infection Which Causes Hæmoglobinuria in Certain Species of Monkey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27494405" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Estimating Geographical Variation in the Risk of Zoonotic Plasmodium knowlesi Infection in Countries Eliminating Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28758162" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Individual-level factors associated with the risk of acquiring human Plasmodium knowlesi malaria in Malaysia: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25272973" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23359830" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increasing incidence of Plasmodium knowlesi malaria following control of P. falciparum and P. vivax Malaria in Sabah, Malaysia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29873683" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Age-Related Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of Severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30889244" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28863470" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28863470" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28863470" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Plasmodium knowlesi and Plasmodium falciparum Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14332847" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A NATURALLY ACQUITED QUOTIDIAN-TYPE MALARIA IN MAN TRANSFERABLE TO MONKEYS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051281" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A large focus of naturally acquired Plasmodium knowlesi infections in human beings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18171245" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27125995" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Predicting the geographical distributions of the macaque hosts and mosquito vectors of Plasmodium knowlesi malaria in forested and non-forested areas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23554413" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Human infections and detection of Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23292346" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28201638" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27619000" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Malaria risk factor assessment using active and passive surveillance data from Aceh Besar, Indonesia, a low endemic, malaria elimination setting with Plasmodium knowlesi, Plasmodium vivax, and Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29565973" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : First case of human infection with Plasmodium knowlesi in Laos.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30949391" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Occupationally Acquired Plasmodium knowlesi Malaria in Brunei Darussalam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707609" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Treatment of Plasmodium knowlesi Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30043723" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Retrospective clinical case series study in 2017 identifies Plasmodium knowlesi as most frequent Plasmodium species in returning travellers from Thailand to Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32005228" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Updates on malaria incidence and profile in Malaysia from 2013 to 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26690736" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Falling Plasmodium knowlesi Malaria Death Rate among Adults despite Rising Incidence, Sabah, Malaysia, 2010-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26690736" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Falling Plasmodium knowlesi Malaria Death Rate among Adults despite Rising Incidence, Sabah, Malaysia, 2010-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4385130" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23216947" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26603174" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19635025" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical and laboratory features of human Plasmodium knowlesi infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27405869" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21762579" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22905799" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30624597" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Deaths From Plasmodium knowlesi Malaria: Case Series and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A study of monkey-malaria and its experimental transmission to man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20779410" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : OBSERVATIONS ON INFECTION BY PLASMODIUM KNOWLESI (APE MALARIA) IN THE TREATMENT OF GENERAL PARALYSIS OF THE INSANE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Duration of Plasmodium knowlesi infections in man
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23087389" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28122651" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical features and management of Plasmodium knowlesi infections in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26671886" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Retinal Changes in Uncomplicated and Severe Plasmodium knowlesi Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723228" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25214480" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23110615" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Laboratory markers of disease severity in Plasmodium knowlesi infection: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27613607" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intravascular haemolysis with haemoglobinuria in a splenectomized patient with severe Plasmodium knowlesi malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Plasmodium knowlesi malaria infection in human
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21265252" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Human Plasmodium knowlesi infections in Klang Valley, Peninsula Malaysia: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509259" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Spontaneous splenic rupture in Plasmodium knowlesi malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26454133" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A case of severe Plasmodium knowlesi in a splenectomized patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21529389" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Plasmodium knowlesi malaria in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24358031" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25301955" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Plasmodium knowlesi malaria during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21762577" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among Humans and Anopheles dirus Mosquitoes, Southern Vietnam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26433222" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Asymptomatic and Submicroscopic Carriage of Plasmodium knowlesi Malaria in Household and Community Members of Clinical Cases in Sabah, Malaysia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19812279" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34620386" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Plasmodium knowlesi detection methods for human infections-Diagnosis and surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19383118" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23294844" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23345297" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24696029" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Combining parasite lactate dehydrogenase-based and histidine-rich protein 2-based rapid tests to improve specificity for diagnosis of malaria Due to Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24548805" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24548805" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Evaluation of three rapid diagnostic tests for the detection of human infections with Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27107287" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20510281" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Artemisinin combination therapy for vivax malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29020373" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27083152" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A zoonotic human infection with simian malaria, Plasmodium knowlesi, in Central Kalimantan, Indonesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29720188" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Two clusters of Plasmodium knowlesi cases in a malaria elimination area, Sabang Municipality, Aceh, Indonesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20350383" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Plasmodium knowlesi in human, Indonesian Borneo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23941258" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Plasmodium knowlesi and HIV co-infection in a German traveller to Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21481643" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Plasmodium knowlesi in a traveller returning to New Zealand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27006963" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837731" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19146706" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23282136" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Ascaris co-infection does not alter malaria-induced anaemia in a cohort of Nigerian preschool children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15991489" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mefloquine resistance reversal action of ketoconazole - a cytochrome P450 inhibitor, against mefloquine-resistant malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6974694" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Antimalarial activity of mefloquine and chloroquine against blood induced Plasmodium knowlesi infection in rhesus monkeys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26930493" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26438871" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Population genomic structure and adaptation in the zoonotic malaria parasite Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24245918" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Susceptibility of human Plasmodium knowlesi infections to anti-malarials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16125588" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21062666" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25629462" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The fluid management of adults with severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23324951" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Fluid resuscitation of adults with severe falciparum malaria: effects on Acid-base status, renal function, and extravascular lung water.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26581060" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The Safety of a Conservative Fluid Replacement Strategy in Adults Hospitalised with Malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35180298" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in Plasmodium knowlesi Malaria (PACKNOW): A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29538635" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859359" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Delayed haemolysis after artesunate therapy in a cohort ofpatients with severe imported malaria due to Plasmodiumfalciparum
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
